Single Agent Vanucizumab (Ro5520985) For Platinum (Pt)-Resistant Recurrent Ovarian Cancer (Oc): Results From A Single Arm Extension Phase Of The Phase I Fih Study.

5549 Background: Vanucizumab is a bi-specific human IgG1 antibody, simultaneously blocking the complementary roles of Ang-2 and VEGF-A induced tumor angiogenesis. Both, VEGF-A and Ang-2 inhibitors are known to be clinically active in ovarian cancer. Hence, co-targeting of both ligands in a bi-specific manner represents an encouraging approach to improve treatment outcomes. Methods: Eligiblepatients (pts) had platinum (Pt)- resistant/refractory epithelial OC (measurable by RECIST 1.1). Pts with history of bowel obstruction, u003e 2 prior lines of systemic chemotherapy, or previous treatments with agents targeting Ang/Tie2 receptor axis were ineligible. Pts were treated with vanucizumab (RP2D) at 30 mg/kg IV Q2W until disease progression or unacceptable toxicity. Primary endpoint was objective response rate (ORR) per RECIST 1.1, with tumor re-assessments every 8 weeks (wks). Results: 41 pts (40 Pt- resistant/ 1 Pt- refractory) with median age of 60 years (range 30-77) were enrolled. 13 (32%) pts were pre-treate...